A
Allogene Therapeutics
A biotechnology company catalyzing cancer treatment through the development of CAR T therapy
At a glance
- Founded
- 2018
- Headquarters
- San Francisco, United States
- Listing
- IPO 2018
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
TPG- PFPfizer
- TRTwo River
- VVVida Ventures
Perceptive Advisors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
67 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Allogene Therapeutics was the backer or acquirer, 2021–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across Allogene Therapeutics's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Allogene Therapeutics deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Allogene Therapeutics's portfolio, mapped.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Allogene Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Allogene Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.